See more : Sakurai Ltd. (7255.T) Income Statement Analysis – Financial Results
Complete financial analysis of Amyris, Inc. (AMRS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Amyris, Inc., a leading company in the Chemicals – Specialty industry within the Basic Materials sector.
You may be interested
- HIRAYAMA HOLDINGS Co.,Ltd. (7781.T) Income Statement Analysis – Financial Results
- Sundaram Multi Pap Limited (SUNDARAM.BO) Income Statement Analysis – Financial Results
- T.RAD Co., Ltd. (7236.T) Income Statement Analysis – Financial Results
- Carlsberg A/S (CABGY) Income Statement Analysis – Financial Results
- China State Construction Development Holdings Limited (0830.HK) Income Statement Analysis – Financial Results
Amyris, Inc. (AMRS)
About Amyris, Inc.
Amyris, Inc., a synthetic biotechnology company, operates in the clean health and beauty, and flavors and fragrance markets in Europe, North America, Asia, and South America. The company manufactures and sells clean beauty, personal care, and health and wellness consumer products, as well as ingredients to the flavor and fragrance, nutrition, food and beverage, and clean beauty and personal care end markets. It offers its products under the Biossance, Pipette, Purecane, Terasana, Costa Brazil, OLIKA, Rose Inc., and JVN brand names. The company has a collaboration agreement with the Infectious Disease Research Institute for the development of a COVID-19 vaccine. The company was formerly known as Amyris Biotechnologies, Inc. and changed its name to Amyris, Inc. in June 2010. Amyris, Inc. was incorporated in 2003 and is headquartered in Emeryville, California.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 269.85M | 341.82M | 173.14M | 152.56M | 80.42M | 143.45M | 77.19M | 34.15M | 43.27M | 41.12M | 73.69M | 146.99M | 80.31M | 64.61M | 13.89M |
| Cost of Revenue | 258.67M | 155.14M | 87.81M | 76.19M | 38.91M | 63.83M | 56.68M | 37.37M | 33.20M | 38.25M | 77.31M | 155.62M | 70.52M | 60.43M | 10.36M |
| Gross Profit | 11.18M | 186.68M | 85.33M | 76.37M | 41.51M | 79.62M | 20.51M | -3.22M | 10.07M | 2.87M | -3.62M | -8.62M | 9.80M | 4.18M | 3.53M |
| Gross Profit Ratio | 4.14% | 54.61% | 49.28% | 50.06% | 51.62% | 55.50% | 26.58% | -9.43% | 23.27% | 6.97% | -4.91% | -5.87% | 12.20% | 6.47% | 25.40% |
| Research & Development | 110.22M | 94.29M | 71.68M | 71.46M | 68.69M | 56.84M | 51.41M | 44.64M | 49.66M | 56.07M | 73.63M | 87.32M | 55.25M | 38.26M | 30.31M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 493.63M | 257.81M | 137.07M | 126.59M | 86.92M | 63.03M | 47.72M | 56.26M | 55.44M | 57.05M | 78.72M | 83.23M | 40.39M | 23.56M | 16.62M |
| Other Expenses | 0.00 | -38.07M | -89.16M | -20.15M | 1.36M | -956.00K | -45.37M | -114.18M | -30.00M | -20.86M | -45.63M | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 603.84M | 352.10M | 208.75M | 198.05M | 155.61M | 119.88M | 99.13M | 105.62M | 105.10M | 113.12M | 152.35M | 170.55M | 95.64M | 61.82M | 46.93M |
| Cost & Expenses | 862.51M | 507.24M | 296.56M | 274.23M | 194.52M | 183.71M | 155.81M | 143.00M | 138.30M | 151.37M | 229.66M | 326.16M | 166.16M | 122.25M | 57.29M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 258.00K | 264.00K | 387.00K | 162.00K | 1.47M | 1.54M | 1.54M | 448.00K | 1.38M |
| Interest Expense | 24.73M | 25.61M | 47.95M | 58.67M | 39.27M | 36.16M | 37.63M | 78.85M | 28.95M | 9.11M | 4.93M | 1.54M | 1.44M | 1.22M | 377.00K |
| Depreciation & Amortization | 27.27M | -25.38M | -77.04M | -20.15M | 4.92M | 11.36M | 11.37M | 12.92M | 14.97M | 16.64M | 14.57M | 11.08M | 7.28M | 5.78M | 2.63M |
| EBITDA | -514.21M | -190.80M | -200.46M | -141.83M | -112.74M | -41.22M | -115.83M | -118.46M | -225.62M | -5.61M | -200.13M | -166.55M | -81.53M | -51.42M | -39.40M |
| EBITDA Ratio | -190.55% | -55.82% | -115.78% | -92.97% | -140.19% | -28.73% | -150.05% | -346.86% | -521.36% | -13.64% | -271.56% | -113.31% | -101.51% | -79.58% | -283.58% |
| Operating Income | -592.67M | -165.42M | -123.42M | -121.67M | -120.95M | -40.26M | -85.92M | -148.53M | -99.83M | -119.62M | -201.82M | -179.17M | -83.79M | -63.41M | -43.40M |
| Operating Income Ratio | -219.63% | -48.39% | -71.29% | -79.76% | -150.40% | -28.07% | -111.31% | -434.90% | -230.69% | -290.90% | -273.86% | -121.89% | -104.33% | -98.14% | -312.41% |
| Total Other Income/Expenses | 54.04M | -106.89M | -200.43M | -120.46M | -28.16M | -36.84M | -10.86M | -69.05M | 102.49M | -116.14M | -3.23M | 213.00K | 2.96M | -1.39M | 857.00K |
| Income Before Tax | -538.63M | -272.31M | -323.85M | -242.14M | -211.35M | -77.10M | -86.78M | -217.58M | 2.66M | -235.75M | -205.05M | -178.96M | -80.83M | -64.80M | -42.54M |
| Income Before Tax Ratio | -199.60% | -79.67% | -187.05% | -158.72% | -262.81% | -53.75% | -112.42% | -637.09% | 6.15% | -573.35% | -278.25% | -121.75% | -100.64% | -100.30% | -306.24% |
| Income Tax Expense | -2.70M | -8.11M | 293.00K | 629.00K | -50.95M | 295.00K | 553.00K | 468.00K | 495.00K | -847.00K | 981.00K | 552.00K | -3.98M | 877.00K | -207.00K |
| Net Income | -535.93M | -264.20M | -324.14M | -242.77M | -211.35M | -77.39M | -87.33M | -217.95M | 2.29M | -235.11M | -205.14M | -178.87M | -81.87M | -64.46M | -41.86M |
| Net Income Ratio | -198.60% | -77.29% | -187.22% | -159.13% | -262.81% | -53.95% | -113.14% | -638.16% | 5.28% | -571.78% | -278.37% | -121.69% | -101.94% | -99.77% | -301.35% |
| EPS | -1.58 | -0.90 | -1.59 | -2.39 | -3.50 | -2.40 | -5.49 | -25.75 | 0.45 | -46.73 | -54.25 | -59.89 | -82.75 | -203.42 | -124.74 |
| EPS Diluted | -1.58 | -0.90 | -1.59 | -2.39 | -3.50 | -2.40 | -4.95 | -25.75 | 0.28 | -46.73 | -54.25 | -59.89 | -82.75 | -203.42 | -124.74 |
| Weighted Avg Shares Out | 339.33M | 292.34M | 203.60M | 101.37M | 60.36M | 32.25M | 15.90M | 8.46M | 5.23M | 5.03M | 3.78M | 2.99M | 989.36K | 316.87K | 335.61K |
| Weighted Avg Shares Out (Dil) | 339.33M | 292.67M | 203.60M | 101.37M | 60.36M | 32.25M | 17.64M | 8.46M | 8.12M | 5.03M | 3.78M | 2.99M | 989.36K | 316.87K | 335.61K |
Squalene Market to Grow by USD 62.9 Million from 2024-2028, Driven by Rising Adoption of UVA/UVB Filters in Sunscreens, Report Powered by AI - Technavio
NEW YORK, Sept. 17, 2024 /PRNewswire/ -- Report on how AI is driving market transformation- The global squalene market size is estimated to grow by USD 62.9 mn from 2024-2028, according to Technavio. The market is estimated to grow at...
Retail investors flock to penny stocks WeWork, Amyris, Proterra
WeWork, a prized startup just four years ago but now a micro-cap, and other penny stocks such as Amyris and Proterra are the latest focus of speculative bets from retail traders, with shares of the financially struggling firms rising in...
AMRS Stock Surges 152% as Amyris Files for Bankruptcy
Amyris (NASDAQ: AMRS ) stock is rising higher on Friday with heavy trading after the biotechnology company filed for bankruptcy. AMRS stock is bouncing back after the company's stock took a beating on Thursday when it first announced its bankruptcy.
Biotech Company Amyris Files for Bankruptcy
Synthetic biotechnology company Amyris filed for Chapter 11 bankruptcy protection as it restructures, leading its share price to drop more than 70% in early trading Thursday.
Why Is Amyris (AMRS) Stock Down 67% Today?
Amyris (NASDAQ: AMRS ) stock is falling on Thursday after the company filed for Chapter 11 bankruptcy protection. According to a press release from Amyris, the company is entering bankruptcy to facilitate a restructuring of its business.
AMYRIS ANNOUNCES OPERATIONAL AND FINANCIAL RESTRUCTURING TO ADVANCE STRATEGIC TRANSFORMATION
Voluntary Chapter 11 Commenced to Finalize Consensual Go-Forward Plan for Amyris' Core Business $190 Million Financing Commitment from Foris Ventures to Support Day-to-Day Operations EMERYVILLE, Calif. , Aug. 9, 2023 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS) ("Amyris" or the "Company"),...
Amyris Warns Of Potential Bankruptcy - Sell
Cash-strapped specialty renewable products developer Amyris remains on life support by largest shareholder and creditor John Doerr. In recent months, Doerr has provided another $157.5 million in secured debt financing thus increasing his total secured debtholdings to $290 million with...
7 Biotech Stocks to Sell in July
Biotech may be a great sector for risk-seeking investors to find opportunity. That said, for every biotech stock worth buying, there are plenty that fit into the “biotech stocks to sell” category.
Is It Time to Buy This Year's Worst-Performing Growth Stocks?
Not all low-priced stocks are appealing for investment, as some remain too unpredictable even at a lower buy-in price. This is a mixed bag and investors should do a deep analysis before investing in market-lagging growth stocks.
Amyris: CEO's Exit Has Negative Implications
The resignation of Amyris' CEO is likely to be viewed as a positive by many, but the implications of this are negative. Management turnover and the engagement of a consulting firm are not signs of a healthy business. Poor communication...
Source: https://incomestatements.info
Category: Stock Reports